Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT03114319
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
- NCT03114319 ↗
- Terminated
- Novartis Pharmaceuticals
- Focused
We haven't built an HCP commentary report on NCT03114319 (TNO155; TNO155 plus nazartinib in advanced solid tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03114319 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 2 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- An Open-label, Multi-center, Phase I, Dose Finding Study of Oral TNO155 in Adult Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Status
- Terminated
- Conditions
- Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC); KRAS G12-mutant NSCLC; Esophageal Squamous Cell Cancer (SCC); Head/Neck SCC; Melanoma; Advanced Gastrointestinal Stromal Tumors (GIST); Advanced NRAS/BRAFT wt Cutaneous Melanoma
- Interventions
- TNO155; TNO155 in combination with EGF816 (nazartinib)
- Arms
- TNO155 · Experimental
- TNO155 in combination with EGF816 (nazartinib) · Experimental
- Enrollment
- 227
- Primary outcomes
- Number of participants with adverse events and serious adverse events
- Number of participants with dose limiting toxicities
- Number of participants with dose interruptions and reductions
- Dose intensity of study drugs
- Sponsor
- Novartis Pharmaceuticals
- Start
- May 26, 2017
- Primary completion
- Jul 4, 2025
- Results posted
- No
- Registry record
- NCT03114319 · updated Jul 9, 2026